AR025459A1 - Antagonistas muscarinicos - Google Patents

Antagonistas muscarinicos

Info

Publication number
AR025459A1
AR025459A1 ARP000104540A ARP000104540A AR025459A1 AR 025459 A1 AR025459 A1 AR 025459A1 AR P000104540 A ARP000104540 A AR P000104540A AR P000104540 A ARP000104540 A AR P000104540A AR 025459 A1 AR025459 A1 AR 025459A1
Authority
AR
Argentina
Prior art keywords
muscarinic antagonists
alkoxy
halogen
alkyl
substituents selected
Prior art date
Application number
ARP000104540A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR025459A1 publication Critical patent/AR025459A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Derivados de amida de compuestos de piperidina 1,4-disustituida de la formula (1) o una sal, éster o solvato farmacéuticamente aceptable del mismo, endonde: Q y Q1 son cada uno -CH=, o uno de Q y Q1 es -CH= y el otro es -N=; X es -CH2- o un resto deformula (2); Y y Z son -C(R5)=, o uno de Y y Z es -C(R5)= yel otro es -N=; R1 es de 1 a 3 sustituyentes seleccionados entre H, halogeno y alcoxi; R2 y R5 son de 1 a 3 sustituyentes seleccionados entre H, halogeno,alquilo y alcoxi; y R3 y R4 son H oa lquilo C1-6. Son antagonistas muscarínicos utiles para el tratamiento de trastornos cognitivos como ser la enfermedad deAlzheimer. También se describen composiciones farmacéuticas y métodos de preparacion.
ARP000104540A 1999-09-22 2000-08-31 Antagonistas muscarinicos AR025459A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40139199A 1999-09-22 1999-09-22

Publications (1)

Publication Number Publication Date
AR025459A1 true AR025459A1 (es) 2002-11-27

Family

ID=23587566

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000104540A AR025459A1 (es) 1999-09-22 2000-08-31 Antagonistas muscarinicos

Country Status (14)

Country Link
EP (1) EP1214299B1 (es)
JP (1) JP2003509494A (es)
CN (1) CN1167682C (es)
AR (1) AR025459A1 (es)
AT (1) ATE264301T1 (es)
AU (1) AU5786300A (es)
CA (1) CA2384018C (es)
CO (1) CO5180624A1 (es)
DE (1) DE60009931T2 (es)
ES (1) ES2215055T3 (es)
HK (1) HK1043590A1 (es)
MX (1) MXPA02003136A (es)
PE (1) PE20010649A1 (es)
WO (1) WO2001021590A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
JP2005506339A (ja) * 2001-10-10 2005-03-03 シェーリング　コーポレイション ムスカリン性アンタゴニストとしてのピペリジン化合物
WO2004069828A1 (ja) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation ピペリジン化合物およびその医薬用途
CA2789014C (en) 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
WO2014122474A1 (en) 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
CA3001873A1 (en) * 2015-11-06 2017-05-11 Neurocrine Biosciences, Inc. N-[2-(1-benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurologicaldiseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US6066636A (en) * 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
TW474933B (en) * 1998-06-30 2002-02-01 Schering Corp Muscarinic antagonists

Also Published As

Publication number Publication date
CA2384018A1 (en) 2001-03-29
CO5180624A1 (es) 2002-07-30
ATE264301T1 (de) 2004-04-15
CA2384018C (en) 2010-01-12
ES2215055T3 (es) 2004-10-01
PE20010649A1 (es) 2001-06-19
DE60009931D1 (de) 2004-05-19
DE60009931T2 (de) 2005-04-07
EP1214299B1 (en) 2004-04-14
WO2001021590A1 (en) 2001-03-29
EP1214299A1 (en) 2002-06-19
MXPA02003136A (es) 2002-09-30
JP2003509494A (ja) 2003-03-11
HK1043590A1 (zh) 2002-09-20
CN1374949A (zh) 2002-10-16
AU5786300A (en) 2001-04-24
CN1167682C (zh) 2004-09-22

Similar Documents

Publication Publication Date Title
MY133992A (en) Muscarinic antagonists
NO990551L (no) Piperidin- og piperazinderivater, og deres anvendelse som muskarine antagonister
NO990671D0 (no) Muskarinantagonistiske etere
NO20005166D0 (no) Nye benzotiofen-, benzofuran- og indolforbindelser, fremgangsmÕte ved deres fremstilling og farmasøytiske sammensetninger inneholdende dem
PE20040687A1 (es) Quinolinas sustituidas como antagonistas del receptor ccr5
JPWO2006046552A1 (ja) 新規な含窒素複素環化合物およびその塩
RU2004130426A (ru) Циклические амиды
AR019167A1 (es) Derivados heteroaromaticos de piperazinas di-n-sustituidas y piperidinas 1,4-disustituidas, composiciones farmaceuticas y el uso de los mismos para lapreparacion de medicamentos
AR043501A1 (es) Derivados de imidazol-4-il-etinil-piridina
AR025459A1 (es) Antagonistas muscarinicos
US2846437A (en) Lower alkyl 4-phenyl-1-(substituted-alkyl) piperidine-4-carboxylates and preparationthereof
SE9703377D0 (sv) New compounds
YU40998A (sh) Derivati supstituisanog 1,2,3,4-tetrahidronaftalina
NZ333513A (en) 1,4-di-substituted piperidines and medicaments useful as muscarinic antagonists
KR960022486A (ko) 신규 티아졸리딘-4-온 유도체
DE60105610D1 (en) Pyrazinonderivate
NO942309L (no) 5-amino-8-methyl-7-pyrrolidinylkinolin-3-carboxylsyrederivater
JP2024020453A (ja) Ｒｏｃｋ阻害剤としての重水素化合物
CA2076146A1 (en) Piperidine derivatives
ECSP003642A (es) Antagonistas muscarinicos
NZ543068A (en) Substituted 4-(alkyl-amide)-piperidine derivatives, processes for their preparation, and pharmaceutical compositions containing them
JPH0558999A (ja) カルバミン酸誘導体及びその製造方法
CA2220140C (en) (2-morpholinylmethyl)benzamide derivatives
ES2289000T3 (es) (4-acilaminopiperidin-1-il)-acetamidas en calidad de antagonistas de neuroquinina.
DE69526595D1 (de) Pyridoncarbonsäurederivate substituiert von bicyclischer aminogruppe, deren ester und salze, und bicyclisches amin als zwischenprodukt davon